Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition

• Main Authors: Hua Cai (Author), Rongrong Zheng (Author), Ningxia Wu (Author), Jiaman Hu (Author), Ruixin Wang (Author), Jianing Chi (Author), Wei Zhang (Author), Linping Zhao (Author), Hong Cheng (Author), Ali Chen (Author), Shiying Li (Author), Lin Xu (Author)
• Format: Book
• Published: MDPI AG, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Chemotherapy-induced side effects restrain anti-tumor efficiency, with hyperlipidemia being the most common accompanying disease to cause treatment failure. In this work, a chimeric peptide-engineered nanomedicine (designated as PRS) was fabricated for the synergistic suppression of tumor growth and...